ORLADEYO® demonstrates strong patient retention1

  • In just over a year following approval, more than 1000 prescriptions have been written1
  • Almost half of patients currently on ORLADEYO were previously taking another prophylactic therapy, including injectable prophylaxis1

More than 75% of patients who started on ORLADEYO remained on therapy for 6 months or longer1,a

aData current as of March 2022.1

It’s important to set expectations with patients starting ORLADEYO

  • The recommended dosage of ORLADEYO is one 150 mg capsule taken orally once daily with food2,b
  • Ensure patients have rescue therapy available for treatment of breakthrough hereditary angioedema (HAE) attacks2
  • Steady state of ORLADEYO is reached in 6 to 12 days, but it may take longer for patients to experience benefit2,3
    • Encourage patients to check in frequently during the first few weeks of treatment4

b A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein or breast cancer resistance protein inhibitors (eg, cyclosporine).1

Many patients are starting—and staying on—ORLADEYO, including those who were previously on injectable prophylaxis.1